{"id":21804,"date":"2024-02-16T11:18:45","date_gmt":"2024-02-16T10:18:45","guid":{"rendered":"http:\/\/mabdesign.fr\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/"},"modified":"2024-02-16T11:26:56","modified_gmt":"2024-02-16T10:26:56","slug":"osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/","title":{"rendered":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033"},"content":{"rendered":"\n<p><a href=\"https:\/\/osivax.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Osivax<\/a>, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06128382\" target=\"_blank\" rel=\"noreferrer noopener\">(NCT06128382<\/a>) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate. <\/p>\n\n<p>Recently, preclinical data published in <a href=\"https:\/\/osivax.com\/osivax-publishes-preclinical-data-for-sarbecovirus-vaccine-candidate-ovx033-in-frontiers-in-immunology\/\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers in Immunology<\/a> demonstrated OVX033&#8217;s proof of cross-protection against three SARS-CoV-2 variants of concern. In a rabbit toxicology study, the vaccine candidate also showed an excellent safety and tolerance profile after intramuscular administration. The first-in-human study will be conducted at the Clinical Investigation Center in Vaccinology Cochin Pasteur (CIC) in Cochin Hospital in Paris (AP-HP, Inserm) under the supervision of Odile Launay, MD, PhD, Professor at Paris Cit\u00e9 University. <a href=\"https:\/\/osivax.com\/pressrelease-firstpatient-of-ovx033-fih\/\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033<\/p>\n","protected":false},"author":3,"featured_media":7695,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-21804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign<\/title>\n<meta name=\"description\" content=\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-16T10:18:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-16T10:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033\",\"datePublished\":\"2024-02-16T10:18:45+00:00\",\"dateModified\":\"2024-02-16T10:26:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\"},\"wordCount\":129,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\",\"name\":\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"datePublished\":\"2024-02-16T10:18:45+00:00\",\"dateModified\":\"2024-02-16T10:26:56+00:00\",\"description\":\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"width\":600,\"height\":152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign","description":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/","og_locale":"en_US","og_type":"article","og_title":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign","og_description":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033","og_url":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/","og_site_name":"MabDesign","article_published_time":"2024-02-16T10:18:45+00:00","article_modified_time":"2024-02-16T10:26:56+00:00","og_image":[{"width":600,"height":152,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","type":"image\/jpeg"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033","datePublished":"2024-02-16T10:18:45+00:00","dateModified":"2024-02-16T10:26:56+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/"},"wordCount":129,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/","url":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/","name":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","datePublished":"2024-02-16T10:18:45+00:00","dateModified":"2024-02-16T10:26:56+00:00","description":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","width":600,"height":152},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-first-participant-in-first-in-human-trial-evaluating-sarbecovirus-vaccine-candidate-ovx033\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/21804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=21804"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/21804\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/7695"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=21804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=21804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=21804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}